Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:N Engl J Med
Asıl Yazarlar: Swain, Sandra M., Baselga, José, Kim, Sung-Bae, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas, Heeson, Sarah, Clark, Emma, Ross, Graham, Benyunes, Mark C., Cortés, Javier
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5584549/
https://ncbi.nlm.nih.gov/pubmed/25693012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1413513
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller